| HOME >> BIOLOGY >> TECHNOLOGY |
manufacturing facility.
(f) Write-offs in the amount of $6.2 million, $1.9 million and $0.1
million during the year ended December 31, 2007, relating to
inventory adjustments recorded in connection with the acquisition of
Biosite, Cholestech and HemoSense, respectively.
(g) Purchase of in-process research and development during the year
ended December 31, 2007 includes a write-off of $169.0 million and
$4.8 million associated with the value of in-process research and
development costs incurred in connection with our acquisition of
Biosite and Diamics, respectively. Purchase of in-process research
and development during the year ended December 31, 2006 includes a
write-off of $5.0 million associated with the value of in-process
research and development costs incurred in connection with our
acquisition of Clondiag.
(h) Write-off of debt origination costs upon early extinguishment of
related debt, which constitutes a charge having a significant
negative impact on results yet does not occur on a consistent or
regular basis in our business in the amount of $15.6 million and
$1.3 million for the year ended December 31, 2007 and 2006,
respectively.
(i) A $3.9 million unrealized foreign currency loss associated with a
cash escrow established in connection with the acquisition of BBI
Holdings Plc, partially offset by a $1.9 million foreign currency
gain realized on the settlement of intercompany notes.
(j) Tax effect on adjustments as discussed above in notes (b), (c), (d),
(f), (h) and (i).
(k) For the year ended December 31, 2007 and 2006, potential dilutive
shares were not used in the calculation of
'/>"/>
| SOURCE Inverness Medical Innovations Copyright©2008 PR Newswire. All rights reserved |